Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31753322 | 0.95 | GPR119 (0.64) | GPR119TRPV4 | |
| SCHEMBL31752283 | 0.91 | GPR119 (0.58) | GPR119TRPV4 | |
| SCHEMBL7251887 | 0.85 | HRH2 (0.52) | GPR119 | |
| SCHEMBL15109863 | 0.85 | GPR119 (0.58) | GPR119 | |
| SCHEMBL1576133 | 0.85 | GPR119 (0.75) | GPR119 | |
| SCHEMBL1574984 | 0.85 | GPR119 (0.75) | GPR119 | |
| SCHEMBL2340177 | 0.84 | GPR119 (0.71) | GPR119 | |
| SCHEMBL1576050 | 0.84 | GPR119 (0.71) | GPR119 | |
| SCHEMBL1575619 | 0.84 | GPR119 (0.74) | GPR119 | |
| SCHEMBL1575291 | 0.84 | GPR119 (0.74) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| US-8993603-B2 | Pharmaceutical composition and method using antifungal agent in combination | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8993603-B2 | Pharmaceutical composition and method using antifungal agent in combination | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8993603-B2 | Pharmaceutical composition and method using antifungal agent in combination | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| EP-1767526-B1 | ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL CONTAINING THESE | TOYAMA CHEMICAL CO LTD (JP) | 2012-10-24 | — | — | EP | disclosed |
| EP-1767526-B1 | ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL CONTAINING THESE | TOYAMA CHEMICAL CO LTD (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-7700623-B2 | Arylamidine derivative, salt thereof, and antifungal containing these | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-7700623-B2 | Arylamidine derivative, salt thereof, and antifungal containing these | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-7700623-B2 | Arylamidine derivative, salt thereof, and antifungal containing these | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20090087480-A1 | PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20090087480-A1 | PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20090087480-A1 | PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20080319016-A1 | Novel Arylamidine Derivative, Salt Thereof, and Antifungal Containing These | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080319016-A1 | Novel Arylamidine Derivative, Salt Thereof, and Antifungal Containing These | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080319016-A1 | Novel Arylamidine Derivative, Salt Thereof, and Antifungal Containing These | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1867332-A1 | PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-12-19 | — | — | EP | disclosed |
| EP-1767526-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF, AND ANTIFUNGAL CONTAINING THESE | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090087480-A1 | PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION | PIK3C3, ARSA, ACR | GPR119 823/4885TRPV4 4684/4885 |
| US-20080319016-A1 | Novel Arylamidine Derivative, Salt Thereof, and Antifungal Containing These | NAT1, ERG28, SLC7A1 | GPR119 295/4885TRPV4 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.